Diurizone Powder

Valsts: Īrija

Valoda: angļu

Klimata pārmaiņas: HPRA (Health Products Regulatory Authority)

Aktīvā sastāvdaļa:

Dexamethasone; Hydrochlorothiazide

Pieejams no:

Vetoquinol Ireland Limited

ATĶ kods:

QC03AX01

SNN (starptautisko nepatentēto nosaukumu):

Dexamethasone; Hydrochlorothiazide

Deva:

0.25, 75.0 milligram(s)/gram

Zāļu forma:

Oral powder

Receptes veids:

POM: Prescription Only Medicine as defined in relevant national legislation

Ārstniecības grupa:

Cattle, Non food-producing horses

Ārstniecības joma:

hydrochlorothiazide, combinations

Ārstēšanas norādes:

Cardiovascular

Autorizācija statuss:

Authorised

Autorizācija datums:

1989-10-11

Produkta apraksts

Health Products Regulatory Authority
28 August 2019
CRN00987J
Page 1 of 4
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Diurizone Powder
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Active Substances
Hydrochlorothiazide
75.0
mg/g
Dexamethasone
0.25
mg/g
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Oral powder.
A fine, free-flowing powder
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle
Horses declared as not being intended for slaughter for human
consumption
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
_Cattle:_
Congestion and oedema of the udder
Persistent oedema during lactation
Pulmonary congestion and oedema
Oedema of surgical wounds
Oedema of allergic conditions
_Horses:_
Generalised congestion and oedema
Oedema of sheath
Anasarca
Oedema in allergic conditions
4.3 CONTRAINDICATIONS
Do not use in pregnant animals. Do not use in animals with viral
infections, during the viraemic phase. Do not use in animals
with diabetes mellitus, congestive heart failure, chronic nephritis,
osteoporosis or glaucoma. Do not use in animals with hepatic
encephalopathy. Do not use in cases of severe hypokalemia. Do not use
in animals with known hypersensitivity to the active
ingredients. Do not use in horses for the treatment of laminitis.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
None.
Health Products Regulatory Authority
28 August 2019
CRN00987J
Page 2 of 4
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY MEDICINAL PRODUCT TO ANIMALS
None.
4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
The association Hydrochlorothiazide and Dexamethasone acetate may
induce hepatic encephalopathy.
Corticosteroids may delay wound healing and the immunosuppressant
actions may weaken resistance to or exacerbate existing
infections.
In the presence of bacterial infection, anti-bacterial therapy is
required when steroids are used.
In the presence of viral infections, steroids may